Clinical Trial Update: Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients [Phase 1, Phase 2]

View source ↗

Summary

A platform phase 1/2 study evaluating novel ruxolitinib combinations in myelofibrosis has been terminated; results from the study have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• Jakafi (ruxolitinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Myelofibrosis | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-08-07